PAA have announced on Friday that Dr Michael Thurn has been appointed as MD & CEO, He initially resigned due to disagreements with the BoD but due to shareholder activism the Bod had been replaced and Dr MT has now been reappointed which is excellent news as he was the driving force in PAA over the last 6 months, anyway the announcement basics are as follows:
PharmAust strengthens executive team with the reappointment of Dr Michael Thurn and new CSO
PharmAust has reappointed Dr Michael Thurn as Managing Director and Chief Executive Officer
Dr Nicky Wallis has joined PharmAust as Chief Scientific Officer
Dr Wallis is a neuroscientist who brings over 12 years of global expertise in preclinical and clinical development, and will lead the evaluation of monepantel as a potential treatment for other neurodegenerative diseases
These appointments are part of a major reset for the Company as it strives to become a global leader in neurodegenerative diseases
Definitely a buy